As we reach the mid-point of 2018, how are approvals of new molecular entities faring? As of the end of June, the FDA had approved 20 NMEs, a similar number as approved this time last year when the...
So which mergers and acquisitions among pharmaceutical companies have made the mark thus far in 2018? DCAT Value Chain Insights takes an inside look. Two $60-billlion deals top the list. First is...
